Eating Disorders News and Research

Latest Eating Disorders News and Research

Age no barrier to disordered eating

Eating disorders are commonly seen as an issue faced by teenagers and young women, but a new study reveals that age is no barrier to disordered eating. In women aged 50 and over, 3.5% report binge eating, nearly 8% report purging, and more than 70% are trying to lose weight.

21 Jun 2012

Sufficient cancer pain relief may mean frequent follow up

US study findings show that just over half of cancer patients receiving outpatient palliative care who have mild or moderate pain intensity at initial consultation, report an increase to moderate or severe pain intensity by first follow up.

20 Jun 2012

Adjuvant chemoradiotherapy boosts esophageal cancer survival

Chemoradiotherapy significantly improves the outcome of patients undergoing surgery for cancer of the esophagus or esophagogastric junction and is well tolerated, suggests research in The New England Journal of Medicine.

7 Jun 2012

Positive updated interim data from Exelixis’ cabozantinib phase 2 trial on CRPC

Exelixis, Inc. today reported positive updated interim data from an ongoing phase 2 trial of cabozantinib in men with metastatic castration-resistant prostate cancer (CRPC) and bone metastases.

6 Jun 2012

Chicago psychological center serves as model for treatment of binge eating

As experts discuss major changes in binge eating, a Chicago psychological center serves as a model for treatment of the most common eating disorder.

5 Jun 2012

Onyx announces data from regorafenib Phase 3 trial on GIST

Onyx Pharmaceuticals today announced data from the Phase 3 GRID (GIST – Regorafenib In Progressive Disease) trial evaluating the investigational drug regorafenib, a Bayer compound, in patients with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) whose disease had progressed despite prior treatment with imatinib and sunitinib.

4 Jun 2012

Lilly, Kowa announce results from PREVAIL U.S. study

Kowa Pharmaceuticals America, Inc. and Eli Lilly and Company today announced results of the PREVAIL U.S. study (Pitavastatin compaREd with praVAstatin In Lowering LDL-C in the U.S.) which evaluated the efficacy of LIVALO (pitavastatin) 4 mg compared with pravastatin 40 mg in reducing low-density lipoprotein cholesterol (LDL-C), the primary endpoint, as well as effects on other lipid parameters and lipoprotein particles in adult patients with primary hyperlipidemia or mixed dyslipidemia.

2 Jun 2012

Doctors may predict girls at increased risk of eating disorders based on food choices

Doctors may be able to predict which girls are at risk of developing eating disorders based on the food choices they make when they are younger, according to a new study by Cincinnati Children's Hospital Medical Center.

30 May 2012

EMA CHMP adopts positive opinion for Pfizer’s axitinib to treat advanced renal cell carcinoma

Pfizer announced today that the Committee for Human Medicinal Products (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion regarding the marketing authorization of axitinib in the European Union (EU), for the treatment of adult patients with advanced renal cell carcinoma (RCC), a type of advanced kidney cancer, after failure of prior treatment with sunitinib or a cytokine.

25 May 2012

Bayer’s Nexavar Phase 3 trial on NSCLC does not meet primary endpoint

Bayer HealthCare Pharmaceuticals and Onyx Pharmaceuticals, Inc. today announced that a Phase 3 trial evaluating Nexavar (sorafenib) tablets in patients with advanced relapsed or refractory non-squamous non-small cell lung cancer (NSCLC) whose disease progressed after two or three previous treatments, did not meet its primary endpoint of improving overall survival.

22 May 2012

Nine fine-grained patterns of Internet usage may indicate depression

In a new study analyzing Internet usage among college students, researchers at Missouri University of Science and Technology have found that students who show signs of depression tend to use the Internet differently than those who show no symptoms of depression.

17 May 2012

Pfizer fails to meet primary endpoint in TORISEL Phase 3 study for advanced RCC

Pfizer Inc announced that the Phase 3 INTORSECT (B1771003) study, evaluating TORISEL(temsirolimus) in patients with advanced renal cell carcinoma (RCC) whose disease had progressed on or after SUTENT (sunitinib malate) therapy, did not meet the primary endpoint of prolonging progression free survival (PFS) when compared to sorafenib.

16 May 2012

CU scientist looks at reward circuits in the brain

Why does one person become anorexic and another obese? A study recently published by a University of Colorado School of Medicine researcher shows that reward circuits in the brain are sensitized in anorexic women and desensitized in obese women.

15 May 2012

NEJM publishes results from Celgene’s REVLIMID phase III studies on MM

Celgene International Sàrl, a subsidiary of Celgene Corporation, today announced that results from three phase III studies evaluating the use of continuous REVLIMID(lenalidomide) treatment in newly diagnosed multiple myeloma (MM) patients or maintenance treatment with lenalidomide following autologous stem cell transplant were published online in the May 10, 2012 edition of the New England Journal of Medicine.

11 May 2012

Researchers create new systematic assessment for malnutrition

A new systematic assessment of malnutrition, created by researchers at Penn State, will aid dietitians and other health care providers in diagnosis and treatment.

4 May 2012

Researchers define structure of key part of human obesity receptor

Medical researchers at the University of Sheffield have defined the structure of a key part of the human obesity receptor- an essential factor in the regulation of body fat- which could help provide new treatments for the complications of obesity and anorexia.

27 Apr 2012

Positive top-line results from Shire’s Vyvanse Phase 2 study on binge eating disorder

Shire plc, the global specialty biopharmaceutical company, today announced positive top-line results from a Phase 2 study to evaluate the safety and efficacy of Vyvanse (lisdexamfetamine dimesylate) Capsules, (CII) in adults with binge eating disorder.

27 Apr 2012

Rise of eating disorders among men and boys

There is an alarming rise of eating disorders among men and boys. Psychologist Deanne Jade, founder of the National Centre For Eating Disorders, says while the route into eating disorders may be different for boys and girls, the underlying causes are all the same.

25 Apr 2012

Eating disorders can be triggered by lack of support following traumatic events

Eating disorders can be triggered by lack of support following traumatic events such as bereavement, relationship problems, abuse and sexual assault, according to research published in the May issue of the Journal of Clinical Nursing. Even changing school or moving home can prove too much for some young people and lead to conditions such as anorexia or bulimia.

25 Apr 2012

Obese men more likely to underestimate their weight than women

When University of Illinois researchers surveyed over 3,500 college applicants, more than a third couldn't report their weight accurately, and overweight and obese men were more likely to underestimate their weight than women.

6 Apr 2012